AVXL (AVXL) Stock Analysis
Verdict: AVOID
Governance proxy fights and zero commercial revenue weigh on AVXL, offset only by a 31-month cash runway for Phase III CNS trials.
Investment score: 30/100
The AI model recommends AVOID for AVXL due to zero revenue, severe technical downtrend, and governance instability, despite a moderate cash buffer.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| CAMP | -1.87 | -347.75 | 20.96 | -0.05 | — | -25.44 |
| RNAC | -1.35 | -1.88 | 158.78 | -0.96 | — | -104.22 |
| IVVD | -1.99 | 1.39 | 3.96 | -0.74 | — | -1.84 |
| GLSI | -10.59 | 76.51 | 0.00 | -10.63 | — | 0.00 |
| ELDN | -2.70 | 4.21 | 0.00 | -2.47 | — | 0.00 |